Leila Russo

589 total citations
13 papers, 342 citations indexed

About

Leila Russo is a scholar working on Cancer Research, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Leila Russo has authored 13 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 8 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Leila Russo's work include Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Genomics and Diagnostics (5 papers). Leila Russo is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer Genomics and Diagnostics (5 papers). Leila Russo collaborates with scholars based in Italy, United States and Belgium. Leila Russo's co-authors include Giuseppe Viale, Patrizia Dell’Orto, Kornélia Polyák, Eric P. Winer, Marco Colleoni, Aditya Bardia, Silvia Dellapasqua, Laura M. Spring, Ian E. Krop and Denise A. Yardley and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Cancer Discovery.

In The Last Decade

Leila Russo

13 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leila Russo Italy	8	256	137	117	80	56	13	342
Ji Won Woo South Korea	10	219 0.9×	118 0.9×	89 0.8×	58 0.7×	82 1.5×	18	352
Flavia Jacobs Italy	11	169 0.7×	134 1.0×	55 0.5×	104 1.3×	57 1.0×	40	311
Michelle K. DeMeo United States	7	314 1.2×	99 0.7×	147 1.3×	109 1.4×	79 1.4×	17	379
Liisa Sailas Finland	7	260 1.0×	179 1.3×	48 0.4×	121 1.5×	81 1.4×	11	412
VJ Suman United States	6	338 1.3×	175 1.3×	220 1.9×	50 0.6×	130 2.3×	15	439
Julie Means‐Powell United States	10	125 0.5×	133 1.0×	290 2.5×	71 0.9×	84 1.5×	12	507
Inge Kemper Netherlands	7	381 1.5×	268 2.0×	94 0.8×	88 1.1×	30 0.5×	11	461
Jurui Luo China	9	162 0.6×	144 1.1×	117 1.0×	100 1.3×	156 2.8×	21	417
Adel Tabchy United States	7	189 0.7×	168 1.2×	123 1.1×	45 0.6×	138 2.5×	14	397
Daniel Schmolze United States	11	213 0.8×	86 0.6×	55 0.5×	130 1.6×	69 1.2×	30	369

Countries citing papers authored by Leila Russo

Since Specialization

Citations

This map shows the geographic impact of Leila Russo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leila Russo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leila Russo more than expected).

Fields of papers citing papers by Leila Russo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leila Russo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leila Russo. The network helps show where Leila Russo may publish in the future.

Co-authorship network of co-authors of Leila Russo

This figure shows the co-authorship network connecting the top 25 collaborators of Leila Russo. A scholar is included among the top collaborators of Leila Russo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leila Russo. Leila Russo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Metzger, Otto, Nabihah Tayob, Giuseppe Viale, et al.. (2024). Abstract PS09-02: Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer. Cancer Research. 84(9_Supplement). PS09–2. 2 indexed citations

Metzger, Otto, Giuseppe Viale, Shayna Stein, et al.. (2021). Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discovery. 11(10). 2474–2487. 148 indexed citations

Viale, Giuseppe, Amy E. Hanlon Newell, Espen J. Walker, et al.. (2019). Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes. Breast Cancer Research and Treatment. 178(2). 451–458. 34 indexed citations

Viale, Giuseppe, Leen Slaets, Femke A. de Snoo, et al.. (2016). Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer. Breast Cancer Research and Treatment. 155(3). 463–469. 16 indexed citations

Ekholm, Maria, Dorthe Grabau, Pär‐Ola Bendahl, et al.. (2015). Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines – a Swedish survey with central re-assessment. Acta Oncologica. 54(7). 1040–1048. 18 indexed citations

Viale, Giuseppe, Leen Slaets, Femke A. de Snoo, et al.. (2015). Abstract P4-11-08: Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial. Cancer Research. 75(9_Supplement). P4–11. 1 indexed citations

Hicks, David G., Patrizia Dell’Orto, Mary Falzon, et al.. (2015). Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies. Applied immunohistochemistry & molecular morphology. 25(5). 313–319. 7 indexed citations

McCullough, Ann E., Patrizia Dell’Orto, Monica M. Reinholz, et al.. (2014). Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Research and Treatment. 143(3). 485–492. 49 indexed citations

Viale, Giuseppe, Leen Slaets, Femke De Snoo, et al.. (2012). Comparison of molecular (BluePrint and MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.. Journal of Clinical Oncology. 30(27_suppl). 32–32. 1 indexed citations

10.

Viale, Giuseppe, Leen Slaets, Femke De Snoo, et al.. (2012). Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.. Journal of Clinical Oncology. 30(15_suppl). 1022–1022. 2 indexed citations

11.

Colleoni, Marco, Leila Russo, & Silvia Dellapasqua. (2011). Adjuvant therapies for special types of breast cancer. The Breast. 20. S153–S157. 25 indexed citations

12.

Tomasello, Giovanni, et al.. (2008). Gastric metastases originating from occult breast lobular carcinoma: diagnostic and therapeutic problems. World Journal of Surgical Oncology. 6(1). 78–78. 36 indexed citations

13.

Marrazzo, Antonio, et al.. (2006). The role of sentinel lymph-node biopsy (SLNB) in the treatment of breast cancer.. PubMed. 58(3). 299–304. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact